VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2016

Jun 10, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2016-06-08

Reporting Person: BOGER JOSHUA S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-06-08	Common Stock	M	5130	$35.35	Acquired	273355	Direct
2016-06-08	Common Stock	S	4930	$94.93	Disposed	268425	Direct
2016-06-08	Common Stock	S	200	$95.57	Disposed	268225	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-08	Stock Option (Right to Buy)	$35.35	M	5130	Disposed	2016-07-19	Common Stock (5130)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	13286	Indirect
Common Stock	122700	Indirect

Footnotes

F1: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

F2: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3: Open market sales reported on this line occurred at a weighted average price of $94.93 (range $94.41 to $95.40).

F4: Open market sales reported on this line occurred at a weighted average price of $95.57 (range $95.56 to $95.57).

F5: Fully vested.